PDCD1 and cancer: Multiple immune checkpoint inhibitors (ICIs) disrupting the PD-1/PD-L1 interaction have been successfully developed, exhibiting durable therapeutic benefits in many cancers, while only a subset of cancer patients benefit from ICIs monotherapy [2, 3].